

Table 9.27
All Lymphoid Neoplasms With Detailed Hodgkin Lymphoma Subtypes^a
SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis
All Races, Females, 2010-2016

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)		
Lymphoid Neoplasm	82,811	72.8 (72.4 , 73.2)	91.1 (90.1 , 92.0)	81.8 (81.4 , 82.3)	63.1 (62.4 , 63.8)			
1 Hodgkin Lymphoma	6,495	88.6 (87.6 , 89.5)	98.1 (96.8 , 98.9)	92.5 (91.6 , 93.4)	60.1 (55.6 , 64.2)			
1(a) Classical Hodgkin lymphoma	6,178	88.2 (87.2 , 89.1)	98.0 (96.7 , 98.8)	92.4 (91.4 , 93.3)	58.0 (53.4 , 62.2)			
1(a)1. Lymphocyte-rich/mixed cellularity/ lymphocyte-depleted	706	83.7 (79.8 , 86.9)	97.7 (84.0 , 99.7)	90.2 (86.3 , 93.0)	66.5 (56.5 , 74.7)			
1(a)1.1 Lymphocyte-rich	162	90.5 (80.6 , 95.4)	100.0 (- , -)	94.7 (84.4 , 98.3)	76.7 (47.3 , 91.1)			
1(a)1.2 Mixed cellularity	499	83.3 (78.6 , 87.0)	96.9 (79.5 , 99.6)	88.6 (83.7 , 92.1)	68.1 (56.2 , 77.4)			
1(a)1.3 Lymphocyte-depleted	45	59.0 (42.9 , 72.0)	100.0 (- , -)	84.6 (58.5 , 94.9)	21.5 (6.6 , 42.0)			
1(a)2. Nodular sclerosis	3,769	92.6 (91.5 , 93.6)	98.4 (96.9 , 99.2)	94.0 (92.8 , 95.0)	64.7 (56.7 , 71.7)			
1(a)3. Classical Hodgkin lymphoma, NOS ^c	1,703	80.1 (77.7 , 82.4)	96.6 (91.9 , 98.6)	89.0 (86.6 , 91.0)	47.7 (40.9 , 54.2)			
1(b) Nodular lymphocyte predominant Hodgkin Lymphoma	317	95.8 (91.5 , 97.9)	100.0 (- , -)	95.9 (89.9 , 98.4)	89.7 (75.6 , 95.9)			
2 Non-Hodgkin lymphoma	74,495	71.8 (71.4 , 72.3)	89.3 (88.0 , 90.5)	80.3 (79.7 , 80.8)	63.7 (63.0 , 64.4)			
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	174	70.4 (57.6 , 80.0)	- (- , -)	83.5 (71.7 , 90.7)	52.9 (29.3 , 71.8)			
4 Lymphoid neoplasm, NOS ^c	1,647	54.1 (51.1 , 57.1)	82.4 (67.2 , 91.0)	76.7 (72.6 , 80.3)	40.0 (36.0 , 43.9)			

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). [Expected survival rates](#) are derived from life tables by socio-economic status, geography and race developed by the SEER program.

^c NOS = Not otherwise specified.

- Statistic not displayed due to less than 25 cases.